Nurix Therapeutics, Inc. NRIX
NASDAQ
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 701.94M | 36.77M | 71.78M | 83.98M | 83.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 701.94M | 36.77M | 71.78M | 83.98M | 83.69M |
| Cost of Revenue | 334.07M | 340.93M | 331.38M | 316.90M | 301.10M |
| Gross Profit | 367.86M | -304.17M | -259.60M | -232.92M | -217.42M |
| SG&A Expenses | 78.21M | 57.01M | 55.70M | 52.74M | 49.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 412.28M | 397.95M | 387.08M | 369.65M | 350.92M |
| Operating Income | 289.66M | -361.18M | -315.30M | -285.67M | -267.23M |
| Income Before Tax | 308.21M | -341.62M | -294.52M | -263.70M | -244.02M |
| Income Tax Expenses | 13.34M | -271.00K | 760.00K | 760.00K | 768.00K |
| Earnings from Continuing Operations | 294.88 | -341.35 | -295.28 | -264.46 | -244.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 294.88M | -341.35M | -295.28M | -264.46M | -244.79M |
| EBIT | 289.66M | -361.18M | -315.30M | -285.67M | -267.23M |
| EBITDA | 297.77M | -353.18M | -307.31M | -277.53M | -259.36M |
| EPS Basic | 2.51 | -3.45 | -3.16 | -3.04 | -2.97 |
| Normalized Basic EPS | 1.64 | -2.16 | -1.97 | -1.90 | -1.85 |
| EPS Diluted | 2.31 | -3.45 | -3.16 | -3.05 | -2.97 |
| Normalized Diluted EPS | 1.52 | -2.16 | -1.97 | -1.90 | -1.85 |
| Average Basic Shares Outstanding | 427.81M | 400.41M | 373.20M | 346.69M | 330.01M |
| Average Diluted Shares Outstanding | 432.40M | 400.41M | 373.20M | 346.69M | 330.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |